It can bind with another HER2 or with its partner HER3, in a process we call dimerization. We’ve thought for many years that we can disrupt dimerization by making antibodies that bind the outside part ...

HER3 functions through its interaction with other ErbB receptors, particularly HER2, forming potent signaling pairs that drive cell survival, proliferation, and metastasis.

Results: Specimens of 110 pts (36/110 luminal, 35/110 HER2-amplified, 40/110 triple-negative) were available for this analysis. 23/110 (21%) specimens showed strong, complete, membranous staining for ...

Access free, up-to-date clinical references about common systemic agents to treat HER2-positive breast cancer. Healio's Clinical Guidance content provides valuable insights for physicians.

615 Background: Somatic mutations in the 4 HER family genes (EGFR, HER2, 3, 4) occur in HER2-positive breast cancer (HER2+ BC). ... 2 HER2, 2 HER3, 5 HER4 mutations) were identified in 6.5 % of HER2+ ...

A particularly aggressive, metastasizing form of cancer, HER2-positive breast cancer, may be treated with nanoscopic particles “imprinted” with specific binding sites for the receptor molecule ...

Patients with high-risk, hormone receptor (HR)-positive, HER2-negative breast cancer treated with presurgical patritumab deruxtecan (HER3-DXd) with or without Femara (letrozole) experienced similar ...

The study investigates the interaction between the human epidermal growth receptor 2 (HER2) and amygdalin, a compound found in peaches, almonds, and apples. To assess the potential of amygdalin ...

Lastly, the HER3-DXd antibody-drug conjugate study presented a potential new therapy for patients with high-risk hormone receptor–positive, HER2-negative breast cancer in the neoadjuvant setting ...